Oral Vesiculobullous Diseases

  • Francina Lozada-Nur
  • Chelsia SimEmail author


  • Match the level of complexity of the management program with the complexity of the patients and use a clinical team approach (dermatologist, PCP, oral hygienist) to facilitate success in complex patients.

  • Ensuring that focus is on paradigms of self-care and education will enhance long-term outcomes and maintain positive relationships with the clinician.


  1. 1.
    Chianini Wu N, Silverman S, Lozada-Nur F, Mayer P, Watson J. Oral lichen planus: patient profile, disease progression and treatment responses. J Am Dent Assoc. 2001;132:901–200.CrossRefGoogle Scholar
  2. 2.
    Lozada F, Silverman S Jr. Erythema multiforme: clinical characteristics and natural history in 50 patients. Oral Surg Oral Med Oral Pathol. 1978;46:628–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Lozada-Nur F, Gorsky M, Silverman S Jr. A follow-up study in 96 patients with oral erythema multiforme. Oral Surg Oral Med Oral Pathol. 1989;67:36–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Ayangco L, Rogers RS 3rd. Oral manifestations of erythema multiforme. Dermatol Clin. 2003;21(1):195–205.CrossRefPubMedGoogle Scholar
  5. 5.
    Silverman S Jr, Gorsky M, Lozada-Nur F, Liu A. A follow-up study in 65 patients with mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol. 1986;61:233–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T, Kirtschig G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich MP, et al. The first international consensus on mucous membrane pem- phigoid: definition, diagnostic criteria, pathogenic factors, medical treatments, and prognostic indicators. Arch Dermatol. 2002;138:370–9.PubMedGoogle Scholar
  7. 7.
    Lozada-Nur F, Miranda C. Oral lichen planus: pathogenesis and epidemiology. Semin Cutan Med Surg. 1997;16:290–5.Google Scholar
  8. 8.
    Chan, L, Olivry, T, Lozada-Nur, F. Oral manifestations of autoimmune blistering diseases from dermatology/diseases of the oral mucosa. 2001.
  9. 9.
    Chanaini-Wu N, Lozada-Nur F, Terrault N. Oral lichen planus and hepatitis C. A review. Med Oral Pathol Oral Radiol Endod. 2004;98(2):171–83.CrossRefGoogle Scholar
  10. 10.
    Bramanti TE, Dekker NP, Lozada-Nur F, Sauk JJ, Regezi JA. Heat shock (stress) proteins and gdT-lymphocytes in oral lichen planus. Oral Surg Oral Med Oral Path. 1995;80:698–70.CrossRefGoogle Scholar
  11. 11.
    Regezi JA, Dekker N, MacPhail L, Lozada-Nur F, et al. Vascular adhesion molecules in oral lichen planus. Oral Surg Oral Med Oral Path. 1996;81:682–90.CrossRefGoogle Scholar
  12. 12.
    Ramirez-Amador V, Dekker NP, Lozada-Nur F, Mirowski GW, MacPhail LA, Regezi JA. Altered interface adhesion molecules in oral lichen planus. J Oral Dis. 1996;2:188–92.CrossRefGoogle Scholar
  13. 13.
    Mirowski GW, Lozada-Nur F, Dekker NP, MacPhail LA, Regezi JA. Altered expression of epithelial integrins and extracellular matrix receptors in oral erythema multiforme. J Cutan Pathol. 1996;23:473–8.CrossRefGoogle Scholar
  14. 14.
    Lozada F. Prednisone and azathioprine in the treatment of oral inflammatory mucocutaneous diseases. Oral Surg Oral Med Oral Pathol. 1981;52:257–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen Planus. J Am Acad Dermatol. 2012;66:752–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Lozada-Nur F, Miranda C. Topical and systemic therapy for oral lichen planus. Semin Cutan Med Surg. 1997;16:295–300.CrossRefPubMedGoogle Scholar
  17. 17.
    Lozada-Nur F, Stroussi H. Tacrolimus-powder in Orabase 0.1% for the treatment of oral lichen Planus and lichenoid reactions: a open clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:744–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Lozada F, Silverman S Jr. Topically applied fluocinonide in adhesive base in the treatment of oral vesiculoerosive diseases. Arch Dermatol. 1980;116:898–901.CrossRefPubMedGoogle Scholar
  19. 19.
    Frey FJ, Amend WJC Jr, Lozada F, Frey BM, Benet LZ. Endogenous hydrocortisone, a possible factor contributing to the genesis of Cushingoid habitus in patients on prednisolone. J Clin Endocrinol Metab. 1981;53:1076–80.CrossRefPubMedGoogle Scholar
  20. 20.
    Benet LZ, Frey FJ, Amend WJC, Lozada F, Frey BM. Endogenous and exogenous gluco-corticoids in cushingoid patients. Drug Intell Clin Pharm. 1982;16:863–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Lozada F, Frey F, Benet L. Prednisone clearance: a possible determinant for gluco-corticoid efficacy in patients with oral vesiculo-erosive diseases. J Dent Res. 1983;62:575–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Lozada-Nur F, Silverman S Jr, Migliorati C. Adverse side effects associated with prednisone in the treatment of oral inflammatory ulcerative diseases. JADA. 1984;109:269–70.Google Scholar
  23. 23.
    Lozada-Nur F, Miranda C, Maleski R. A double blind clinical trial on the efficacy and toxicity of clobetasol ointment in Orabase and fluocinonide ointment in Orabase for the treatment of chronic oral inflammatory diseases. Oral Surg Oral Med Oral Pathol. 1994;77:598–604.CrossRefPubMedGoogle Scholar
  24. 24.
    Mc Caughey C, Machen M, Bennet R, et al. Pimecrolimus 1% cream for erosive oral lichen planus: a 6-week randomized, double-blind, vehicle controlled study with a 6-week open-label extension to assess efficacy and safety. J Eur Acad Dermatol. 2011;9:1061–7.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Division of Oral Medicine, Department of Oro-facial ScienceUniversity of California, San Francisco School of Dentistry San FranciscoSan FranciscoUSA
  2. 2.Department of Oral Maxillofacial Surgery, National Dental Center, Clinical Lecturer, Faculty of DentistryNational University of SingaporeSingaporeSingapore

Personalised recommendations